An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia
Xue-Ying Li,Jie-Jing Qian,Min Yang,Yi Zhang,Sha-Sha Wang,Hai-Tao Meng,Wen-Juan Yu,Hong-Yan Tong,Xiu-Jin Ye,Jie Jin,Hong-Hu Zhu
DOI: https://doi.org/10.1111/bjh.16661
2020-01-01
British Journal of Haematology
Abstract:Philadelphia (Ph) chromosome-positive acute lymphoblastic leukaemia (Ph + ALL) is the most common subtype of adult ALL.1 The use of tyrosine kinase inhibitors (TKIs) plus intensive chemotherapy as a first-line treatment regimen has significantly improved the outcomes of Ph + ALL.2-10 A series of practice-changing studies including imatinib, dasatinib or ponatinib combined with Hyper-CVAD achieved complete remission (CR) rates of 93–98% and an overall survival (OS) of 43–76%, respectively.2, 3, 6, 9 However, Ravandi et al. reported that 74% of patients failed to complete the intended eight cycles of treatment, and early death occurred in 13% of patients during induction.6 The proper balance between the intensity of chemotherapy and compliance and safety needs to be explored in the future. To avoid the cytotoxicity of chemotherapy, the GIMEMA group first employed a completely chemo-free induction with imatinib or dasatinib plus prednisone (DP) in elderly Ph + ALL patients, and reported a 100% CR rate, and 48% and 74% relapse rates when using imatinib alone as postremission treatment.4, 9 To explore whether employing dasatinib plus prednisone as induction and consolidation could diminish relapse, we conducted a retrospective review of 13 adult patients with Ph + ALL under this completely oral and chemo-free model. The study was a single-centre, retrospective analysis. We included all newly diagnosed Ph + ALL adult patients who were treated at our centre from February 1, 2016 to February 1, 2020 with a regimen including DP as induction and consolidation therapy. The induction treatment included dasatinib (100 mg/day) and prednisone (1 mg/kg/day) for 28 days. After achieving CR, consolidation included dasatinib (100 mg/day) for 28 days (d1–d28) and prednisone (1 mg/kg/day) for 7 days (d1–d7) for at least two cycles, followed by an allogeneic haematopoietic stem cell transplantation (allo-HSCT) as soon as possible if a suitable donor was available. Patients without suitable donor were treated according to the treating physicians’ discretion. Response was assessed following the National Comprehensive Cancer Network (NCCN) Guidelines. Complete molecular response (CMR) was defined as the absence of a detectable BCR-ABL1 transcript with a sensitivity of 0·01%. Major molecular response (MMR) was defined as a 3-log reduction in transcripts for BCR-ABL compared to that at diagnosis. Minimal residual disease (MRD) was detected by Q-PCR for BCR-ABL transcript and flow cytometry (sensitivity for positive value ≥1 × 10−4) simultaneously. The characteristics of all 13 Ph + ALL patients are shown in Table 1 and Figure S1. There were seven males and six females, and the median age was 41 years (range, 16–73 years). The median white blood cell (WBC) count and platelet (PLT) count were 65 × 109/l (range, 3·0–400 × 109/l) and 28 × 109/l (range, 4–150 × 109/l), respectively. Seven patients had the p190 form of BCR-ABL, and six had the p210 form. All 13 patients (100%) achieved a CR at the end of one cycle of induction therapy. The median time to CR was 28 days (range, 23–55 days). The rates of MMR and CMR at the end of induction were 38·5% (5/13) and 15·4% (2/13), respectively. The median hospitalization time for induction treatment was 17 days (range, 6–25 days). After CR, all patients completed at least two cycles of consolidation therapy using DP, six patients received allo-HSCT, and others continued consolidation using dasatinib plus prednisone for 2–4 cycles; chemotherapy-based treatment was added for those patients who were MRD-positive (Figure S1). The treatment was well tolerated. No patients had grade 3–4 non-haematological adverse events or discontinued treatment during the induction phase. Three patients had pleural effusions that were successfully corrected by discontinuing therapy temporarily for a median of six days (range, 4–10 days); thereafter, the schedule was resumed for the full dose. BCR-ABL1 transcript levels decreased rapidly after induction and the first and second courses of consolidation therapy Fig 1A. The BCR-ABL transcript levels were 96%, 0·25%, 0·04%, and 0·03% before induction and at 1, 2 and 3 months after induction, respectively (compared to pretreatment, all P < 0·05). Patients with the p190 form had a more rapid molecular response than patients with the p210 form at one month (BCR-ABL transcript, 0·2% vs. 6·9%, P = 0·045). Similarly, the MRD level detected by flow cytometry showed a rapid decrease. The rates of MRD-negative patients were 62%, 89% and 82% at 1, 2 and 3 months, respectively (Fig 1B). A T315I mutation was detected in all five relapsed cases, which occurred at 4, 10, 13, 15 and 16 months after receiving dasatinib. The last follow-up was in February 15, 2020, and the median follow-up time was 23 months (range, 3–39 months). In total, five patients relapsed at 3, 9, 12, 14 and 15 months after achieving CR. One patient died of transplantation-related mortality at six months (two months after HSCT) and one died of relapse at 28 months. Six patients received allo-HSCT after 2–3 courses of consolidation, fioe patients were still alive at the last follow-up (four in CR1 and one in CR2), and one died of transplantation-related mortality. The two-year OS and DFS (disease-free survival) of the total population were 90·9% and 45·5%, respectively (Fig 1C). Patients who received HSCT (n = 6) had a trend toward higher DFS compared with those who received chemotherapy (n = 7) (Fig 1D, P = 0·23). In this small-cohort study, we reported the preliminary results of using an oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation in 13 adult patients with Ph + ALL. CR (100%) and MMR (38·5%) were achieved at the end of induction, which is concordant to a previous report.4 Dasatinib is a second-generation TKI with greater activity than imatinib, which contributed to the high CR and MMR rate. Although an excellent result for a TKI plus a steroid as induction therapy, the outcome was still poor because 74% of patients suffered relapse if TKI only was continued as the postremission treatment.4 The T315I mutation was the most common, especially after dasatinib.10 Not surprisingly, all five relapsed patients acquired a T315I mutation after receiving dasatinib in our study. Once the T315I mutation occurs, ponatinib might be the best choice,11 although the response duration is relatively short. To avoid relapse, we added prednisone to dasatinib during consolidation and subsequent HSCT, and found that 38·5% of patients relapsed. This chemo-free treatment provided patients with good performance and fewer complications at the time of HSCT, which resulted in a 90·9% OS and 45·5% DFS. The good safety of this regimen may lie in the dasatinib used for up to 28 days as one course with an interruption of 7–14 days rather than its continuous use. Moreover, prednisone was used for a shortened time of 28 days during induction and for only seven days in each consolidation course, which reduced the risk of infections. In summary, this is the first report of a chemo-free regimen as induction and consolidation therapy and showed not only high CR and MMR rates but also a high quality of life during consolidation in an outpatient model. Further research is needed to diminish relapse and improve the long-term survival of Ph + ALL patients. This work was supported by grants from the National Natural Science Foundation of China (81970133 and 81820108004) The authors declare to have no potential conflicts of interest regarding the present work. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.